Macrophage polarization may be reprogrammed to tumor cell killing by treatment with tyrosine kinase inhibitors sunitinib and sorafenib, or fenretinide [4-hydroxy (phenyl) retinamide], which inhibit STAT3 or STAT6 in macrophages, thereby blocking IL-10 secretion [295,296]. This evidence concerns the gene IL10 and neoplasm.